Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

被引：0
|
作者：
Baglioni, Piero [1 ]
机构：
[1] Ctr Hosp St Jean DAngely, St Jean Dangely, France
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2017年 / 377卷 / 21期
关键词：
SITAGLIPTIN; MELLITUS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：2097 / 2098
页数：2
相关论文
共 50 条
  • [1] Canagliflozin and cardiovascular and renal events in type 2 diabetes
    Guthrie, Robert
    POSTGRADUATE MEDICINE, 2018, 130 (02) : 149 - 153
  • [2] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
    Neal, Bruce
    Perkovic, Vlado
    Mahaffey, Kenneth W.
    de Zeeuw, Dick
    Fulcher, Greg
    Erondu, Ngozi
    Shaw, Wayne
    Law, Gordon
    Desai, Mehul
    Matthews, David R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07): : 644 - 657
  • [3] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Reply
    Neal, Bruce
    Perkovic, Vlado
    Matthews, David R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (21): : 2099 - 2099
  • [4] Canagliflozin and cardiovascular outcomes in Type 2 diabetes
    Sarraju, Ashish
    Spencer-Bonilla, Gabriela
    Rodriguez, Fatima
    Mahaffey, Kenneth W.
    FUTURE CARDIOLOGY, 2020, 17 (01) : 39 - 48
  • [5] Renal effects of canagliflozin in patients with Type 2 diabetes
    Wong, Yip Fong
    Shao, Yanli
    Sum, Chee Fang
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S119 - S120
  • [6] Renal effects of canagliflozin in type 2 diabetes mellitus
    Perkovic, Vlado
    Jardine, Meg
    Vijapurkar, Ujjwala
    Meininger, Gary
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (12) : 2219 - 2231
  • [7] Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
    Perkovic, V.
    Jardine, M. J.
    Neal, B.
    Bompoint, S.
    Heerspink, H. J. L.
    Charytan, D. M.
    Edwards, R.
    Agarwal, R.
    Bakris, G.
    Bull, S.
    Cannon, C. P.
    Capuano, G.
    Chu, P. -L.
    De Zeeuw, D.
    Greene, T.
    Levin, A.
    Pollock, C.
    Wheeler, D. C.
    Yavin, Y.
    Zhang, H.
    Zinman, B.
    Meininger, G.
    Brenner, B. M.
    Mahaffey, K. W.
    McGuire, Darren K.
    Holman, Rury
    Home, Philip
    Scharfstein, Dan
    Parfrey, Patrick
    Shahinfar, Shahnaz
    August, Phyllis
    Chang, Tara
    Sinha, Arjun D.
    Januzzi, James
    Kolansky, Daniel
    Amerena, John
    Hillis, Graham
    Gorelick, Philip
    Kissela, Brett
    Kasner, Scott
    Lindley, Richard
    Fulcher, Greg
    Ounadjela, Souhila
    Hufert, Karina
    von Ingersleben, Gabriele
    Gaglia, Jason
    Harris, Ronald
    Hudson, Margo
    Turchin, Alexander
    Cheifetz, Adam
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24): : 2295 - 2306
  • [8] Type-2-Diabetes: Canagliflozin reduces cardiovascular Risk
    Lichert, Frank
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2017, 142 (22) : 1647 - 1647
  • [9] Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial
    Wada, Takashi
    Mori-Anai, Kazumi
    Kawaguchi, Yutaka
    Katsumata, Hideyuki
    Tsuda, Hidetaka
    Iida, Mitsutaka
    Arakawa, Kenji
    Jardine, Meg J.
    JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (01) : 54 - 64
  • [10] Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program
    Mahaffey, Kenneth W.
    Neal, Bruce
    Perkovic, Vlado
    de Zeeuw, Dick
    Fulcher, Greg
    Erondu, Ngozi
    Shaw, Wayne
    Sun, Tao
    Desai, Mehul
    Matthews, David R.
    CIRCULATION, 2017, 136 (24) : E454 - E455
12345